Dose Limiting Toxicities | List of Frontiers open access articles

Clinical Trial

Published on 13 Dec 2022

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

in Cancer Immunity and Immunotherapy

Weston L. Daniel
Ulrike Lorch
Scott Mix
Alice S. Bexon

Frontiers in Immunology

doi 10.3389/fimmu.2022.1073777

6,941 views
28 citations

Original Research

Published on 09 Feb 2023

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

in Cancer Immunity and Immunotherapy

Ann W. Silk
Brendan Curti
Jennifer Bryan
Tracie Saunders
Weichung Shih
Michael P. Kane
Phoebe Hannon
Christopher Fountain
Jessica Felcher
Andrew Zloza

Frontiers in Oncology

doi 10.3389/fonc.2023.1108341

4,555 views
8 citations

Original Research

Published on 14 Sep 2022

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

in Alloimmunity and Transplantation

Elizabeth Stenger
Cynthia R. Giver
Amelia Langston
Daniel Kota
Pankoj Kumar Das
Raghavan Chinnadurai
Jacques Galipeau
Edmund K. Waller
Muna Qayed

Frontiers in Immunology

doi 10.3389/fimmu.2022.959658

6,465 views
17 citations

Original Research

Published on 31 Oct 2023

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

in Cancer Immunity and Immunotherapy

Katherine E. R. Smith
Kah-Whye Peng
Jose S. Pulido
Adam J. Weisbrod
Carrie A. Strand
Jacob B. Allred
Alysha N. Newsom
Lianwen Zhang
Nandakumar Packiriswamy
Timothy Kottke

Frontiers in Immunology

doi 10.3389/fimmu.2023.1279387

8,678 views
29 citations

Original Research

Published on 06 Aug 2020

Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

in Head and Neck Cancer

Devale Tousif
Vinu Sarathy
Rajesh Kumar
Radheshyam Naik

Frontiers in Oncology

doi 10.3389/fonc.2020.01284

4,582 views
9 citations

Original Research

Published on 29 Sep 2022

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma

in Skin Cancer

Shaheer Khan
Sapna P. Patel
Alexander N. Shoushtari
Grazia Ambrosini
Serge Cremers
Shing Lee
Lauren Franks
Shahnaz Singh-Kandah
Susana Hernandez
Naomi Sender

Frontiers in Oncology

doi 10.3389/fonc.2022.975643

6,169 views
8 citations

Original Research

Published on 27 Jan 2022

Impact of Body Composition on Prognosis and Dose-Limiting Toxicities on Metastatic Colorectal Cancer

in Clinical Nutrition

David da Silva Dias
Mafalda Machado
Carolina Trabulo
Beatriz Gosálbez
Paula Ravasco

Frontiers in Nutrition

doi 10.3389/fnut.2021.671547

6,058 views
21 citations

Articles

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma

Impact of Body Composition on Prognosis and Dose-Limiting Toxicities on Metastatic Colorectal Cancer